Engineering Hafnium Oxide-Based Nanoplatforms for Precision Radiosensitization.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41588825.
- Also identified by DOI 10.1002/adhm.202505200.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hafnium oxide (HfO<sub>2</sub>)-based nanomaterials are emerging as powerful tools to enhance radiotherapy by utilizing their high atomic number (Z). By depositing a greater radiation dose directly within tumors, they offer a promising route to improve treatment efficacy. This review traces the development of HfO<sub>2</sub> nanoradiosensitizers, starting with the clinically established NBTXR3, an approved hafnium-based benchmark for several solid tumors. We analyze the structural characteristics and radiosensitization mechanisms of nanoscale HfO<sub>2</sub>, which include improved X-ray absorption, radical generation, and immunomodulation. Key synthesis methods such as sol-gel, precipitation, and hydrothermal approaches are evaluated in detail, with emphasis on their tunable parameters and reproducibility. Recent progress focuses on material optimization through size control, surface engineering, composite design, and Hf-MOFs, as well as combination strategies. Despite encouraging preclinical results, challenges remain in scalable fabrication, long-term biosafety, and clinical translation. Future directions point toward smart stimuli-responsive platforms and multimodal theranostic systems. This review highlights the potential of HfO<sub>2</sub> to precision radiotherapy while acknowledging existing translational challenges.
Medical subject headings
- Oxides
- Radiation-Sensitizing Agents
- Hafnium
- Neoplasms
- Nanostructures